Abstract
Abstract
Purpose
Black and Latinx MSM and transgender POC disproportionately experience new HIV diagnoses. Determining effective HIV prevention methods requires the inclusion of these communities in research and thorough post-trial experience evaluations. This study sought to evaluate the experiences of Black and Latinx MSM and transgender POC in HIV prevention research and identify facilitators and barriers to continued trials participation.
Methods
A survey was developed in partnership with the community engagement team based on emerging themes during research participant check-ins with the team. The survey was built in REDCap and distributed to participants via text message. The survey assessed experiences with the research process time commitments, study responsibilities, compensation, experiences with Truvada®, characteristics of the research study team and site, barriers to continued study participation, willingness to participate in future studies, and overall satisfaction. All statistical analysis was completed in Stata.
Results
Forty-four participants were enrolled in the study. Most participants (98%) were satisfied with their experiences in HIV prevention research. Job or school schedules were the most frequently cited barrier to study participation while Truvada® provision and adequate study visit compensation, length, number, and frequency were facilitators. Participants reported that research staff made them feel comfortable when talking about sexual behaviors, alcohol use, mental health, drug use, housing problems, violence in relationships, and legal problems.
Conclusions
Evaluating the experiences of key communities in HIV prevention research can help identify barriers and facilitators to clinical trials engagement and improve the design of future trials.
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Sociology and Political Science,Anthropology,Health (social science)
Reference24 articles.
1. Centers for Disease Control and Prevention. HIV Surveillance Report, 2019. 2021 May. Report No.: vol, 32. Available from: http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html
2. Richardson S, Seekaew P, Koblin B, Vazquez T, Nandi V, Tieu H-V. Barriers and facilitators of HIV vaccine and prevention study participation among Young Black MSM and transwomen in New York City. PLoS ONE. 2017;12:e0181702.
3. Huamani KF, Metch B, Broder G, Andrasik M. A Demographic analysis of racial/ethnic minority enrollment into HVTN preventive early phase HIV vaccine clinical trials conducted in the United States, 2002–2016. Public Health Rep. 2019;134:72–80.
4. Djomand G, Katzman J, di Tommaso D, Hudgens MG, Counts GW, Koblin BA, et al. Enrollment of racial/ethnic minorities in NIAID-funded networks of HIV vaccine trials in the United States, 1988 to 2002. Public Health Rep. 2005;120:543–8.
5. Castillo-Mancilla JR, Cohn SE, Krishnan S, Cespedes M, Floris-Moore M, Schulte G, et al. Minorities Remain underrepresented in HIV/AIDS research despite access to clinical trials. HIV Clin Trials. 2014;15:14–26.